Product Images Opsumit
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Opsumit NDC 66215-501 by Actelion Pharmaceuticals Us, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Chemical Structure - opsumit 01
Figure 1 - opsumit 02
This appears to be a table showing the interaction of the drug macitentan and other drugs (Sidonati, Coue, Cyclosporine-a, Avce, Ketoconazole, and Ritampin) in terms of their estimated impact on AUCw (Area Under Concentration Curve) with respective point estimates and 0-90% confidence intervals. The recommendation for each interaction is either "No dose adjustment" or "Avoid".*
Figure 2 - opsumit 03
This is a tabular representation of clinical trial results in which 242 participants were treated with OPSUMIT 10mg and 250 were treated with a placebo. The table shows the number at risk and the percentage for each group over a period of several months from treatment start. The Hazard Ratio is 0.547 and Logrank p-value is <.0001, suggesting that OPSUMIT 10mg is effective in reducing the risk of cardiovascular disease compared to placebo.*
Figure 3 - opsumit 04
This is a table showing the hazard ratio and confidence interval of various factors on the primary end point in clinical trials of a drug called OPSUMIT. The factors include age, gender, race, comorbidities, geographical region, and baseline characteristics. The data on patients under 18 is also mentioned.*
Figure 4 - opsumit 05
This is the summary of a clinical trial evaluating the efficacy of OPSUMIT 10 mg compared to a placebo. The data shows the percentage of patients who remained event-free (Kaplan-Meier) at different time points over a 62-month period. The hazard ratio, confidence interval, and logrank p-value are also provided. The number of patients at risk and the months from the start of treatment are shown in a table. The text ends abruptly with a single digit, making it unclear whether there is further information.*
Figure - opsumit 06
This is a description of acceptable birth control options, including various methods such as the pill, intrauterine devices, condoms, diaphragms, cervical caps, spermicides, and implants. The different options are separated into four categories, with each category consisting of possible combinations of methods. Some of the methods listed include hormonal birth control, barrier methods, and surgical options.*
PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Carton - opsumit 07
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.